EP4203916A1 - Perforation de la muqueuse - Google Patents
Perforation de la muqueuseInfo
- Publication number
- EP4203916A1 EP4203916A1 EP21772669.4A EP21772669A EP4203916A1 EP 4203916 A1 EP4203916 A1 EP 4203916A1 EP 21772669 A EP21772669 A EP 21772669A EP 4203916 A1 EP4203916 A1 EP 4203916A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pharmaceutically active
- microneedle system
- mucosa
- microneedle
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004877 mucosa Anatomy 0.000 title claims abstract description 63
- 239000004480 active ingredient Substances 0.000 claims abstract description 49
- 239000010409 thin film Substances 0.000 claims abstract description 34
- 229920000642 polymer Polymers 0.000 claims abstract description 25
- 239000011159 matrix material Substances 0.000 claims abstract description 11
- 230000004888 barrier function Effects 0.000 claims abstract description 9
- 229920002988 biodegradable polymer Polymers 0.000 claims abstract description 6
- 239000004621 biodegradable polymer Substances 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 6
- 239000013543 active substance Substances 0.000 claims description 60
- -1 antidiabetics Substances 0.000 claims description 20
- 229920002678 cellulose Polymers 0.000 claims description 12
- 239000001913 cellulose Substances 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 11
- 235000010443 alginic acid Nutrition 0.000 claims description 10
- 229920000615 alginic acid Polymers 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 229920002674 hyaluronan Polymers 0.000 claims description 8
- 229960003160 hyaluronic acid Drugs 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 229910000831 Steel Inorganic materials 0.000 claims description 5
- 239000003862 glucocorticoid Substances 0.000 claims description 5
- 239000010959 steel Substances 0.000 claims description 5
- 229940036555 thyroid hormone Drugs 0.000 claims description 5
- 239000005495 thyroid hormone Substances 0.000 claims description 5
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 claims description 4
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 4
- 229920000936 Agarose Polymers 0.000 claims description 4
- 239000001904 Arabinogalactan Substances 0.000 claims description 4
- 229920000189 Arabinogalactan Polymers 0.000 claims description 4
- 241000416162 Astragalus gummifer Species 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- 229920000926 Galactomannan Polymers 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
- 239000004373 Pullulan Substances 0.000 claims description 4
- 229920001218 Pullulan Polymers 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 229920001615 Tragacanth Polymers 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- 239000000783 alginic acid Substances 0.000 claims description 4
- 229960001126 alginic acid Drugs 0.000 claims description 4
- 150000004781 alginic acids Chemical class 0.000 claims description 4
- 235000019312 arabinogalactan Nutrition 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 235000010418 carrageenan Nutrition 0.000 claims description 4
- 229920001525 carrageenan Polymers 0.000 claims description 4
- 239000000679 carrageenan Substances 0.000 claims description 4
- 229940113118 carrageenan Drugs 0.000 claims description 4
- 229940045110 chitosan Drugs 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 235000019426 modified starch Nutrition 0.000 claims description 4
- 229920001206 natural gum Polymers 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 229920002401 polyacrylamide Polymers 0.000 claims description 4
- 229920000058 polyacrylate Polymers 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000019423 pullulan Nutrition 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 235000010487 tragacanth Nutrition 0.000 claims description 4
- 239000000196 tragacanth Substances 0.000 claims description 4
- 229940116362 tragacanth Drugs 0.000 claims description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 4
- 208000001953 Hypotension Diseases 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 229940035676 analgesics Drugs 0.000 claims description 3
- 230000000954 anitussive effect Effects 0.000 claims description 3
- 239000000730 antalgic agent Substances 0.000 claims description 3
- 230000003288 anthiarrhythmic effect Effects 0.000 claims description 3
- 230000007131 anti Alzheimer effect Effects 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000003266 anti-allergic effect Effects 0.000 claims description 3
- 230000003178 anti-diabetic effect Effects 0.000 claims description 3
- 230000002921 anti-spasmodic effect Effects 0.000 claims description 3
- 239000000043 antiallergic agent Substances 0.000 claims description 3
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 239000000739 antihistaminic agent Substances 0.000 claims description 3
- 229940125715 antihistaminic agent Drugs 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000000939 antiparkinson agent Substances 0.000 claims description 3
- 229940124575 antispasmodic agent Drugs 0.000 claims description 3
- 239000003434 antitussive agent Substances 0.000 claims description 3
- 229940124584 antitussives Drugs 0.000 claims description 3
- 239000000496 cardiotonic agent Substances 0.000 claims description 3
- 230000003177 cardiotonic effect Effects 0.000 claims description 3
- 239000000919 ceramic Substances 0.000 claims description 3
- 239000002934 diuretic Substances 0.000 claims description 3
- 229940030606 diuretics Drugs 0.000 claims description 3
- 239000003172 expectorant agent Substances 0.000 claims description 3
- 230000003419 expectorant effect Effects 0.000 claims description 3
- 229940066493 expectorants Drugs 0.000 claims description 3
- 239000003163 gonadal steroid hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 239000003326 hypnotic agent Substances 0.000 claims description 3
- 230000000147 hypnotic effect Effects 0.000 claims description 3
- 208000021822 hypotensive Diseases 0.000 claims description 3
- 230000001077 hypotensive effect Effects 0.000 claims description 3
- 239000004081 narcotic agent Substances 0.000 claims description 3
- 229940125723 sedative agent Drugs 0.000 claims description 3
- 239000000932 sedative agent Substances 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 description 20
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 16
- 239000000126 substance Substances 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 239000002609 medium Substances 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 11
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 11
- 229960004242 dronabinol Drugs 0.000 description 11
- 210000002200 mouth mucosa Anatomy 0.000 description 11
- 230000004907 flux Effects 0.000 description 10
- 239000008363 phosphate buffer Substances 0.000 description 9
- 239000010634 clove oil Substances 0.000 description 8
- 210000000214 mouth Anatomy 0.000 description 8
- 238000005192 partition Methods 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 239000010408 film Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- YLXIPWWIOISBDD-NDAAPVSOSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;4-[(1r)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CNC[C@H](O)C1=CC=C(O)C(O)=C1 YLXIPWWIOISBDD-NDAAPVSOSA-N 0.000 description 5
- SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 5
- 244000223014 Syzygium aromaticum Species 0.000 description 5
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 5
- 229960003990 apomorphine hydrochloride Drugs 0.000 description 5
- 210000003238 esophagus Anatomy 0.000 description 5
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 5
- 229960000658 sumatriptan succinate Drugs 0.000 description 5
- KQKPFRSPSRPDEB-XERRXZQWSA-N 1-[3-[2-[bis(trideuteriomethyl)amino]ethyl]-1h-indol-5-yl]-n-methylmethanesulfonamide Chemical compound C1=C(CS(=O)(=O)NC)C=C2C(CCN(C([2H])([2H])[2H])C([2H])([2H])[2H])=CNC2=C1 KQKPFRSPSRPDEB-XERRXZQWSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 4
- HGASFNYMVGEKTF-UHFFFAOYSA-N octan-1-ol;hydrate Chemical compound O.CCCCCCCCO HGASFNYMVGEKTF-UHFFFAOYSA-N 0.000 description 4
- 230000000149 penetrating effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- 239000004753 textile Substances 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 244000028344 Primula vulgaris Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- WXXSNCNJFUAIDG-UHFFFAOYSA-N riociguat Chemical compound N1=C(N)C(N(C)C(=O)OC)=C(N)N=C1C(C1=CC=CN=C11)=NN1CC1=CC=CC=C1F WXXSNCNJFUAIDG-UHFFFAOYSA-N 0.000 description 3
- 229960000529 riociguat Drugs 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 3
- 229960000499 ulipristal acetate Drugs 0.000 description 3
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 2
- NDAUXUAQIAJITI-LBPRGKRZSA-N (R)-salbutamol Chemical compound CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-LBPRGKRZSA-N 0.000 description 2
- OZOMQRBLCMDCEG-CHHVJCJISA-N 1-[(z)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N/N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-CHHVJCJISA-N 0.000 description 2
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 108010079458 CBLB502 Proteins 0.000 description 2
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 2
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 2
- 239000005770 Eugenol Substances 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 2
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 description 2
- ICMGLRUYEQNHPF-UHFFFAOYSA-N Uraprene Chemical compound COC1=CC=CC=C1N1CCN(CCCNC=2N(C(=O)N(C)C(=O)C=2)C)CC1 ICMGLRUYEQNHPF-UHFFFAOYSA-N 0.000 description 2
- 102000002852 Vasopressins Human genes 0.000 description 2
- 108010004977 Vasopressins Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 229960005260 amiodarone Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 229940125688 antiparkinson agent Drugs 0.000 description 2
- 229960004046 apomorphine Drugs 0.000 description 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 229960000396 atropine Drugs 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229950011318 cannabidiol Drugs 0.000 description 2
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 2
- 229960003120 clonazepam Drugs 0.000 description 2
- 229960001987 dantrolene Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 description 2
- 229950009493 entolimod Drugs 0.000 description 2
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 2
- 229960001690 etomidate Drugs 0.000 description 2
- 229960002217 eugenol Drugs 0.000 description 2
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 2
- 229960004381 flumazenil Drugs 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229960003883 furosemide Drugs 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 229950008204 levosalbutamol Drugs 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 229960004391 lorazepam Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 2
- 229960003793 midazolam Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 2
- 229960004127 naloxone Drugs 0.000 description 2
- 229960001136 obidoxime chloride Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229960002657 orciprenaline Drugs 0.000 description 2
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 2
- JHZHWVQTOXIXIV-UHFFFAOYSA-N oxo-[[1-[3-[4-(oxoazaniumylmethylidene)pyridin-1-yl]propyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCCN1C=CC(=C[NH+]=O)C=C1 JHZHWVQTOXIXIV-UHFFFAOYSA-N 0.000 description 2
- ZIFJVJZWVSPZLE-UHFFFAOYSA-N oxo-[[1-[[4-(oxoazaniumylmethylidene)pyridin-1-yl]methoxymethyl]pyridin-4-ylidene]methyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C1=CC(=C[NH+]=O)C=CN1COCN1C=CC(=C[NH+]=O)C=C1 ZIFJVJZWVSPZLE-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 2
- 229960004134 propofol Drugs 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 239000006068 taste-masking agent Substances 0.000 description 2
- 229960000195 terbutaline Drugs 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 210000003813 thumb Anatomy 0.000 description 2
- 230000003195 tocolytic effect Effects 0.000 description 2
- 229950009520 trimedoxime bromide Drugs 0.000 description 2
- 229960001130 urapidil Drugs 0.000 description 2
- 229960003726 vasopressin Drugs 0.000 description 2
- 230000002618 waking effect Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- 208000000003 Breakthrough pain Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000001734 eugenia caryophyllata l. bud oleoresin Substances 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0061—Methods for using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0625—Mouth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3295—Multiple needle devices, e.g. a plurality of needles arranged coaxially or in parallel
- A61M5/3298—Needles arranged in parallel
Definitions
- the present invention relates to a kit comprising at least one microneedle system and at least one dosage form for the transmucosal administration of at least one pharmaceutically active substance, wherein the at least one dosage form for the transmucosal administration of at least one pharmaceutically active substance preferably comprises an oral thin film, this kit for use in the treatment of a patient, the use of a microneedle system for reducing the permeation barrier of a mucosa for at least one pharmaceutically active ingredient and a method for treating a patient, wherein first a microneedle system is applied to a site of a patient's mucosa and removed again, and then an oral Thin film, comprising at least one matrix polymer and at least one pharmaceutically active agent, on the site of the mucosa to which the microneedle system has been applied and removed again, au f is brought or wherein the microneedle system is applied to the mucosa simultaneously with a dosage form for transmucosal administration of at least one pharmaceutically active ingredient
- Pharmaceutically active ingredients can be administered via the mucosa with appropriate dosage forms.
- Oral thin films for example, are suitable for this purpose.
- Oral thin films are thin films containing at least one pharmaceutically active ingredient that are applied directly to a mucosa (mucous membrane), preferably the oral mucosa, and preferably dissolve there.
- a mucosa mucous membrane
- These are, in particular, thin polymer-based films containing active substance which, when applied to a mucous membrane, in particular the oral mucosa, release the active substance directly into the latter.
- This dosage form has the advantage that the active ingredient is largely absorbed through the oral mucosa, for example, and thus the "first-pass metabolism" that occurs with the conventional dosage form of an active ingredient in tablet form is avoided.
- the active ingredient can be dissolved in the film, be emulsified or dispersed.
- the active substance is absorbed particularly quickly there.
- the absorption route via the oral mucosa is thus characterized by a relatively rapid passage of the active substance or permeation of the active substance.
- an effective increase in blood pressure can be measured as pharmacological evidence after just two minutes.
- OTFs are also preferred for indications that require a rapid onset of action, such as pain, nausea, dizziness, seizures, cardiac arrest, but also for the regulation of high blood pressure or blood sugar levels.
- Suitable administration forms include, for example, textile carriers, for example made of cotton or cellulose, which are impregnated with a solution or suspension of the at least one pharmaceutically active ingredient.
- Medical tamponades for example, such as those used in dentistry, are suitable here.
- Clove oil or its main component eugenol, lavender oil or its main component linalool, methyl salicylate or ethanolic mixtures with glycerol and limonene are suitable as solvents.
- Clove oils include clove blossom oil, clove leaf oil and clove stalk oil and are usually obtained by steam distillation from the various plant parts of the clove tree, Syzygium aromaticum (Myrtaceae).
- Suitable amounts of active ingredient present in such textile carriers are, for example, 50 g per 100 g of textile carrier.
- the mucosa represents a very hydrophilic permeation barrier (it consists of more than 90% water)
- the active ingredients to be applied there should be at least readily water-soluble and thus generally more hydrophilic than lipophilic. This can be achieved, for example, by administering pharmaceutically acceptable salts of drugs.
- the readily water-soluble hydrochlorides of the opioid bases fentanyl and buprenorphine, which are used instead of the bases themselves, in particular for the treatment of breakthrough pain, should be mentioned here.
- the invention was therefore based on the object of providing a way of briefly and reversibly reducing the permeation barrier of the mucosa in order to ensure advantageous absorption of pharmaceutically active substances, in particular of lipophilic pharmaceutically active substances, in particular with a logP greater than 3 or pharmaceutically active substances with a molecular weight > 300 g/mol.
- kits comprising at least one microneedle system and at least one dosage form for transmucosal administration of at least one pharmaceutically active substance, in particular an oral thin film comprising at least one matrix polymer and at least one pharmaceutically active substance.
- microneedles has the advantage that the permeation barrier of the mucosa is temporarily and reversibly reduced and thus an advantageous absorption of pharmaceutically active substances, in particular of lipophilic pharmaceutically active substances, preferably with a logP greater than 3 or pharmaceutically active substances with a molecular weight > 300 g/mol.
- microneedles is understood to mean needles, preferably made of a hard material, with a length of 5 to 1000 ⁇ m.
- the length to diameter ratio is preferably from 5:1 to 1000:1.
- the kit according to the invention is preferably characterized in that the at least one administration form for transmucosal administration comprises an oral thin film, the oral thin film comprising a matrix polymer and at least one pharmaceutically active substance.
- the oral thin film may be single-layered or multi-layered.
- the kit according to the invention is preferably characterized in that the at least one matrix polymer comprises a water-soluble and/or water-swellable polymer.
- Water-soluble and/or water-swellable polymers include chemically very different, natural or synthetic polymers whose common feature is their solubility or swellability in water or aqueous media.
- the kit according to the invention is preferably characterized in that the at least one matrix polymer is selected from the group consisting of starch and starch derivatives, dextrans, cellulose derivatives such as carboxymethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, hydroxypropylethyl cellulose, sodium carboxymethyl cellulose, ethyl or propyl cellulose, polyacrylic acids, polyacrylates , polyvinylpyrrolidones, polyvinyl alcohols, poly(lactide-co-glycoid), hyaluronic acid, polyethylene oxide polymers, polyacrylamides, polyethylene glycols, gelatin, collagen, alginates, pectin, pullulan, tragacanth, chitosan, alginic acid, arabinogalactan, galactomannan, agar, agarose, carrageenan and natural gums , where this group is not final.
- hyaluronic acid particularly preferred are hyaluronic acid, cellulose derivatives, alginates and/or poly(lactide-co-glycoid) since they are polymers of biological origin and should therefore be pharmaceutically acceptable.
- the at least one pharmaceutically active substance contained in the oral thin film according to the invention is not subject to any restriction.
- the kit according to the invention is preferably characterized in that the at least one pharmaceutically active substance comprises a pharmaceutically active substance with a logP>3 and/or with a molecular weight of greater than 300 g/mol.
- the kit according to the invention is also preferably characterized in that the at least one pharmaceutically active substance has a logP > 2, preferably greater than 2.2 or 2.4 or 2.6 or 2.8 or 3.0 or 3.2 or 3, 4 or 3.6 or 3.8 or 4 or 4.2 or 4.4 or 4.6 or 4.8 or 5 or 6 or 7.
- the n-octanol-water partition coefficient K ow (also notations such as octanol/water partition coefficient are common and correct) is a dimensionless partition coefficient known to those skilled in the art, which is the ratio of the concentrations of a chemical in a two-phase system of n-octanol and water and is therefore a measure of the hydrophobicity or hydrophilicity of a substance.
- the logP value is the common logarithm of the n-octanol-water partition coefficient K ow .
- Kow is greater than one when a substance is more soluble in fat-like solvents such as n-octanol and less than one when it is more soluble in water.
- log P is positive for lipophilic substances and negative for hydrophilic substances.
- the at least one pharmaceutically active ingredient preferably has a molecular weight of more than 300 g/mol or more than 1000 g/mol, preferably more than 1500 g/mol or more than 2000 g/mol, in particular more than 2500 g/mol or more than 3000 g/mol or more than 3500 g/mol or more than 4000 g/mol or more than 4500 g/mol or more than 5000 g/mol.
- the kit according to the invention is preferably characterized in that the at least one pharmaceutically active ingredient has a water solubility of less than 1.0 mg/ml, preferably less than 0.5 mg/ml or 0.1 mg/ml or 0.05 mg/ml or 0.001 mg/ml (at 20°C).
- the at least one pharmaceutically active ingredient in the kit according to the invention is preferably from the group consisting of hypnotics, sedatives, antieleptics, waking amines, psychoneurotropics, neuroleptics, neuromuscle blockers, antispasmodics, antihistamines, antiallergics, cardiotonics, antiarrhythmics, diuretics, hypotensives, vasopressors, Antitussives, expectorants, analgesics, thyroid hormones, sex hormones, glucocorticoid hormones, antidiabetics, antitumor agents, antibiotics, chemotherapeutics, narcotics, anti-Parkinson agents, anti-Alzheimer agents and/or triptans, this group not being final.
- the at least one pharmaceutically active ingredient preferably comprises riociugat, tetrahydrocannabinol, cannabidinol, dronabinol, thyroid hormones and/or insulin, since these drugs have so far eluded a successful parenteral route of administration.
- the at least one pharmaceutically active agent preferably comprises an agent from the group of emergency medications.
- emergency medications are preferably selected from the group comprising adrenaline, amiodarone, antidiuretic hormone, apomorphine, atropine, butylscopolaminium bromide, clonazepam, dantrolene, dexamethasone, diazepam, entolimod, etomidate, flumazenil, furosemide, glucagon, glucocorticoids, glucose, haloperidol, heparin, ketamine, Levosalbutamol, lidocaine, lorazepam, metoprolol, midazolam, morphine, naloxone, nitroglycerin, obidoxime chloride, orciprenaline, organic nitrates, propofol, salbutamol, terbutaline, theophylline, tocolytic, trimedoxime bromide and/or ura
- the amount of active ingredient in the oral thin film depends on its kind and is usually 0.01 to 70% by weight, preferably 0.1 to 50% by weight, particularly preferably 1 to 40% by weight based on that Total weight of the oral thin film.
- the oral thin film also contains at least one excipient selected from the group consisting of colorants, flavorings, sweeteners, taste-masking agents, surfactants, enhancers, pH regulators, preservatives, antioxidants and/or emollients.
- excipients are preferably contained in the oral thin film each in an amount of 0.001 to 20% by weight.
- the basis weight of the oral thin film is preferably about 40 to 300 g/m 2 , more preferably about 100 to 250 g/m 2 .
- a microneedle system also referred to as a microneedle array, preferably comprises a system comprising a multiplicity of microneedles on a carrier.
- the needles which preferably have a length of 5 ⁇ m to 1000 ⁇ m, can be made of different materials, such as ceramics, steel, polymers or SiCh.
- the kit according to the invention is preferably characterized in that the microneedle system is a microneedle system based on glass, SiCh, steel, ceramics, starch and starch derivatives, dextrans, cellulose derivatives such as carboxymethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose, hydroxypropylethyl cellulose, sodium carboxymethyl cellulose, ethyl or propyl cellulose, Polyacrylic acids, polyacrylates, polyvinylpyrrolidones, polyvinyl alcohols, poly(lactide-co-glycoid), hyaluronic acid, polyethylene oxide polymers, polyacrylamides, polyethylene glycols, gelatin, collagen, alginates, pectin, pullulan, tragacanth, chitosan, alginic acid, arabinogalactan, galactomannan, agar, agarose, carrageenan and natural gums, this group
- Microneedle systems based on hyaluronic acid, cellulose derivatives, alginates and/or poly(lactide-co-glycoid) are particularly preferred, since they are polymers of biological origin and should therefore be pharmaceutically compatible (except for specific allergic reactions to these substances).
- Suitable microneedle systems are known to those skilled in the art and are described, for example, in US7658728, US7785301 or US8414548, the content of which is hereby incorporated in its entirety. Suitable microneedle systems are available, for example, under the trade name "AdminPatch” from the company “nanobioSciences” (CA, USA).
- the kit according to the invention is preferably characterized in that the microneedle system has microneedles with a length of 100 ⁇ m to 600 ⁇ m, preferably 250 ⁇ m to 350 ⁇ m, particularly preferably about 300 ⁇ m.
- the kit according to the invention is also preferably characterized in that the microneedle system has 30 to 400, preferably 200 to 250 microneedles per cm 2 . In another embodiment, the kit according to the invention is preferably characterized in that the microneedle system has 39 microneedles per cm 2 .
- the present invention also relates to the kit according to the invention as described above for use in treating a patient.
- the present invention also relates to the use of a microneedle system, as described above, for reducing or lowering the permeation barrier of a mucosa for at least one pharmaceutically active substance.
- a mucosa includes, in particular, the human oral mucosa.
- the at least one pharmaceutically active ingredient according to this use is to be understood as defined above.
- the present invention further relates to a method for treating a patient, comprising the steps of a) applying a microneedle system to a site of a patient's mucosa, b) removing the microneedle system and c) applying an oral thin film comprising at least one matrix polymer and at least one pharmaceutically active Active substance on the part of the mucosa to which the microneedle system was applied in step a) and removed again in step b).
- the mucosa preferably includes the human oral mucosa.
- microneedle system and the at least one pharmaceutically active substance are to be understood as defined above.
- the microneedle system is preferably pressed onto the patient's mucosa with a pressure of 1 to 5N, preferably about 3N.
- the pressing time is preferably 2 to 20 seconds, particularly preferably 5 to 15 seconds and in particular about 10 seconds.
- the microneedle system is then removed and the oral thin film is applied to the same site, preferably within 5 to 15 seconds, preferably within 5 seconds.
- the present invention also relates to a method for treating a patient, comprising the steps of a) application of a microneedle system to a site of a patient's mucosa, b) simultaneous application of a dosage form for transmucosal administration of at least one pharmaceutically active agent to the side of the microneedle system which does not contact the mucosa.
- the mucosa preferably includes the human oral mucosa.
- microneedle system and the at least one pharmaceutically active substance are to be understood as defined above.
- the microneedle system is preferably pressed onto the patient's mucosa with a pressure of 1 to 5N, preferably about 3N.
- the administration form for the transmucosal administration of at least one pharmaceutically active substance can be, for example, a textile carrier, such as a tamponade used in dentistry, which is impregnated with a solution or suspension of the at least one pharmaceutically active substance.
- the present invention also relates to a biodegradable microneedle system comprising at least one pharmaceutically active ingredient and at least one biodegradable polymer.
- microneedles is understood to mean needles, preferably made of a hard material, with a length of 5 to 1000 ⁇ m. The length to diameter ratio is preferably from 5:1 to 1000:1.
- microneedle system After the microneedle system has been administered, it dissolves in the patient's mouth, releasing the pharmaceutically active ingredient it contains.
- the biodegradable microneedle system according to the invention is further preferably characterized in that the microneedle system has microneedles with a length of 100 ⁇ m to 500 ⁇ m, preferably 250 ⁇ m to 350 ⁇ m and/or 50 to 400, preferably 200 to 250 microneedles per cm 2 .
- the biodegradable microneedle system according to the invention is further preferably characterized in that the at least one biodegradable polymer is a polymer based on sugar, hyaluronic acid or polyvinylpyrrolidone.
- the at least one pharmaceutically active substance contained in the biodegradable microneedle system according to the invention is not subject to any restriction.
- the biodegradable microneedle system according to the invention is preferably characterized in that the at least one pharmaceutically active substance comprises a pharmaceutically active substance with a logP>3 and/or with a molecular weight of greater than 300 g/mol.
- the biodegradable microneedle system according to the invention is also preferably characterized in that the at least one pharmaceutically active ingredient has a logP > 2, preferably greater than 2.2 or 2.4 or 2.6 or 2.8 or 3.0 or 3.2 or 3 ,4 or 3.6 or 3.8 or 4 or 4.2 or 4.4 or 4.6 or 4.8 or 5 or 6 or 7.
- the n-octanol-water partition coefficient K ow (also spellings such as octanol/water partition coefficient are common and correct) is a dimensionless partition coefficient known to those skilled in the art that indicates the ratio of the concentrations of a chemical in a two-phase system of n-octanol and water and thus a measure of the hydrophobicity or hydrophilicity of a substance is.
- the logP value is the common logarithm of the n-octanol-water partition coefficient K ow .
- Kow is greater than one when a substance is more soluble in fat-like solvents such as n-octanol and less than one when it is more soluble in water.
- log P is positive for lipophilic substances and negative for hydrophilic substances.
- the at least one pharmaceutically active ingredient preferably has a molecular weight of more than 300 g/mol or more than 1000 g/mol, preferably more than 1500 g/mol or more than 2000 g/mol, in particular more than 2500 g/mol or more than 3000 g/mol or more than 3500 g/mol or more than 4000 g/mol or more than 4500 g/mol or more than 5000 g/mol.
- the biodegradable microneedle system according to the invention is preferably characterized in that the at least one pharmaceutically active substance has a water solubility of less than 1.0 mg/ml, preferably less than 0.5 mg/ml or 0.1 mg/ml or 0.05 mg/ml. ml or 0.001 mg/ml (at 20°C).
- the at least one pharmaceutically active ingredient is preferably not present in the biodegradable microneedle system in the form of a salt.
- the at least one pharmaceutically active ingredient in the biodegradable microneedle system according to the invention is preferably from the group consisting of hypnotics, sedatives, antieleptics, waking amines, psychoneurotropics, neuroleptics, neuromuscle blockers, antispasmodics, antihistamines, antiallergics, cardiotonics, antiarrhythmics, diuretics, hypotensives, Vasopressors, antitussives, expectorants, analgesics, thyroid hormones, sex hormones, glucocorticoid hormones, antidiabetics, antitumor agents, antibiotics, chemotherapeutics, narcotics, anti-Parkinson agents, anti-Alzheimer agents and/or triptans, this group not being final.
- the at least one pharmaceutically active agent preferably comprises riociugat, tetrahydrocannabinol, cannabidinol, dronabinol, thyroid hormones, apomorphine hydrochloride, adrenaline hydrogen tartrate and/or insulin, since these agents have hitherto eluded a successful parenteral route of administration.
- the at least one pharmaceutically active agent preferably comprises an agent from the group of emergency medications.
- emergency medications are preferably selected from the group comprising adrenaline, amiodarone, antidiuretic hormone, apomorphine, atropine, butylscopolaminium bromide, clonazepam, dantrolene, dexamethasone, diazepam, entolimod, etomidate, flumazenil, furosemide, glucagon, glucocorticoids, glucose, haloperidol, heparin, ketamine, Levosalbutamol, lidocaine, lorazepam, metoprolol, midazolam, morphine, naloxone, nitroglycerin, obidoxime chloride, orciprenaline, organic nitrates, propofol, salbutamol, terbutaline, theophylline, tocolytic, trimedoxime bromide and/or ura
- the amount of active substance in the biodegradable microneedle system according to the invention depends on its type and is usually 0.01 to 70% by weight, preferably 0.1 to 50% by weight, particularly preferably 1 to 40% by weight, based on the total weight of the oral thin film.
- the biodegradable microneedle system according to the invention also contains at least one auxiliary selected from the group consisting of dyes, flavorings, sweeteners, taste-masking agents, surfactants, enhancers, pH regulators, preservatives, antioxidants and/or plasticizers.
- excipients are preferably contained in the oral thin film each in an amount of 0.001 to 20% by weight.
- Eugenol is preferably present as an enhancer in the biodegradable microneedle system according to the invention.
- the present invention further relates to a biodegradable microneedle system as described above for use as a medicament.
- the present invention also relates to a biodegradable microneedle system as described above for use as a medicament for application to the oral mucosa of a mammal, in particular for application to the human oral mucosa.
- FIG. 3 Comparison of in vitro permeation profiles of a saturated
- FIG. 4 Comparison of in vitro permeation profiles of a saturated
- the active substance flux after pretreatment with a microneedle system is higher by a factor of 2.0 compared to administration without pretreatment.
- FIG. 5 Comparison of in vitro permeation profiles of a self-dissolving microneedle system applied directly into the mucosa and loaded with sumatriptan succinate on the in vitro mucosa model according to example 5.
- the comparative example was the same system but applied inversely, ie with the needle side up and not invading the mucosa.
- To the in vivo contact pressure in the oral cavity To simulate, the microneedle systems were weighed down from above with lead balls as weights, both in the comparison and in the example of the invention.
- the active substance flux with the microneedle system applied into the mucosa is higher by a factor of 2.0 compared to the system without penetrating it.
- the 1st permeation value after 10 minutes for the example according to the invention is higher by a factor of about 4 compared to the comparative example.
- FIG. 6 Comparison of in vitro permeation profiles of a self-dissolving microneedle system applied directly into the mucosa and loaded with adrenaline hydrogen tartrate on the in vitro mucosa model according to example 6.
- the comparative example was the same system but applied inversely, ie with the needle side up and not invading the mucosa.
- the microneedle systems were weighed down from above with lead balls as weights, both in the comparison and in the example according to the invention.
- the active substance flux with the microneedle system applied into the mucosa is four times higher than with the system without penetrating it.
- FIG. 7 Comparison of in vitro permeation profiles of a self-dissolving microneedle system applied directly into the mucosa and loaded with salbutamol sulfate on the in vitro mucosa mode according to example 7.
- the comparative example was the same system but applied inversely, ie with the needle side up and not invading the mucosa.
- the microneedle systems were weighed down from above with lead balls as weights, both in the comparison and in the example according to the invention.
- the active substance flux with the microneedle system applied into the mucosa is higher by a factor of 2 compared to the system without penetrating it.
- FIG. 8 Comparison of in vitro permeation profiles of a self-dissolving microneedle system applied directly into the mucosa and loaded with apomorphine hydrochloride on the in vitro mucosa model according to example 8.
- the comparison example was the same system but applied inversely, ie with the needle side up and not invading the mucosa.
- To the in vivo contact pressure in the oral cavity To simulate, the microneedle systems were weighed down from above with lead balls as weights, both in the comparison and in the example of the invention.
- the active substance flux with the microneedle system applied into the mucosa is higher by a factor of 3 compared to the system without penetrating it.
- FIG. 9 Comparison of in vitro permeation profiles of a self-dissolving microneedle system applied directly into the mucosa and loaded with sumatriptan base on the in vitro mucosa model according to example 9.
- the comparative example was the same system but applied inversely, ie with the needle side up and not invading the mucosa.
- the microneedle systems were weighed down from above with lead balls as weights, both in the comparison and in the example according to the invention. An active ingredient flux could not be measured in the comparative example. In contrast, a high active substance flux could be observed in the microneedle system applied to the mucosa.
- FIG. 10 Comparison of in vitro permeation profiles of an oral thin film containing ulipristal acetate on the in vitro mucosa model according to example 10. A flux of active substance could only be observed after pretreatment with a microneedle system. Without pretreatment, no permeated active substance could be detected.
- the donor and acceptor media used were each selected with regard to the solubility of the example active substances
- the donor solutions used were applied directly to the mucosa surface using pipettes.
- the amount of donor solutions for example active substances 1, 2 and 3 was 150 ⁇ l in each case.
- the contact pressure was 3 N by thumb pressure, controlled using a table scale.
- the pressing time was 10 see.
- Example 4 the donor solution was injected (900 ⁇ l) onto or into the dental tamponade used (length and diameter each 1 cm).
- the microneedle system was fixed to the underside of the tamponade and applied together perpendicularly through the head of the Franz cells to the mucosa surface and fixed in a fixed position with a suitable plug and with moderate pressure.
- Example 5-9 drug-loaded biodegradable microneedle systems were evaluated using Franz diffusion cells as described above.
- Example 10 an oral thin film containing an active ingredient was applied to the mucosa surface that had been pretreated analogously to Examples 1 to 3 with the “AdminPatchTM” microneedle system (needle length 600 ⁇ m).
- a saturated solution of riociguat in clove oil (Primavera® bio clove bud, Oy-Mittelberg, Germany) was used as the donor solution.
- Dermatosed skin from the esophagus of a pig with a layer thickness of 400 ⁇ m was used as a skin model.
- a saturated solution of human insulin in natural human saliva was used as the donor solution. Dermatosed skin from the esophagus of a pig with a layer thickness of 400 ⁇ m was used as a skin model.
- Phosphate buffer pH 5.5
- Tween® 20 an organic solubilizer for maintaining “sink” conditions
- a saturated solution of tetrahydrocannabinol in clove oil (Primavera® bio Nelkenknospe, Oy-Mittelberg, Germany) was used as the donor solution.
- Dermatosed skin from the esophagus of a pig with a layer thickness of 400 ⁇ m was used as a skin model.
- CBD cannabidiol
- Phosphate buffer pH 5.5
- Tween® 20 an organic solubilizer for maintaining “sink” conditions
- a saturated solution of tetrahydrocannabinol in clove oil (Primavera® bio Nelkenknospe, Oy-Mittelberg, Germany) was used as the donor solution. Dermatosed skin from the esophagus of a pig with a layer thickness of 400 ⁇ m was used as a skin model.
- Phosphate buffer pH 7.4 without further additives was used as the acceptor medium; As a water-soluble salt, sumatriptan succinate is very soluble in this acceptor.
- the donor system was a polyvinylpyrrolidone-based microneedle system loaded with sumatripan succinate, which dissolves on contact with water and temperatures > 32 °C.
- sumatriptan succinate, polyvinylpyrrolidone, polysorbate 80 and glycerol were dissolved in water in proportions of 5:20:1:1:73 (each in % by weight).
- the final solution was poured into silicone needle-negative matrices, the surface of which was vapor-deposited with a thin layer of platinum.
- the negative matrices were then dried overnight at room temperature. After the drying process, the dried microneedle systems were carefully pressed out of the matrices and stored away from moisture until further use.
- the active ingredient content was 4.25 mg sumatriptan succinate per 0.785 cm 2 system or 5.41 mg/cm 2 .
- Dermatosed skin from the esophagus of a pig with a layer thickness of 400 ⁇ m was used as a skin model.
- microneedle system remained in the mucosa throughout the permeation period, with the cell head also being filled with lead balls to reduce the in vivo contact pressure (e.g. between the lower jaw and the oral mucosa) in the to simulate the oral cavity.
- a separating film based on siliconized PET polyethylene terephthalate was placed in between to protect the self-dissolving microneedle system from the lead bullets.
- Phosphate buffer pH 6.0 containing 0.1% by weight of L-ascorbic acid was used as the acceptor medium; Adrenaline hydrogen tartrate is very soluble in this acceptor.
- the biodegradable microneedle system was produced and used analogously to example 5, with adrenaline hydrogen tartrate being used as the pharmaceutically active ingredient.
- Phosphate buffer pH 7.4 without further additives was used as the acceptor medium; Salbutamol sulfate is very soluble in this acceptor.
- biodegradable microneedle system was produced and used analogously to example 5, with salbutamol sulfate being used as the pharmaceutically active ingredient.
- Phosphate buffer pH 6.8 containing 0.1% by weight of L-ascorbic acid was used as the acceptor medium; Apomorphine hydrochloride is very soluble in this acceptor.
- biodegradable microneedle system was produced and used analogously to example 5, with apomorphine hydrochloride being used as the pharmaceutically active ingredient.
- Phosphate buffer pH 6.0
- Tween 20 was used as the acceptor medium; Sumatriptan base is very soluble in this acceptor.
- the biodegradable microneedle system was produced and used analogously to example 5, with sumatriptan base being used as the pharmaceutically active ingredient.
- the preparation of the oral thin film was as follows:
- the oral thin film had the following composition (in percent by mass):
- Phosphate buffer pH 7.4 with 2% by weight Tween 20 was used as the acceptor medium; Ulipristal acetate is very soluble in this acceptor.
- the surface of the mucosa was treated with the microneedle system "AdminPatchTM” (needle length 600 pm) from the company “nanobioSciences” (CA, USA) made of steel with a contact pressure of 3 N by thumb pressure, controlled using a table scale for 10 seconds.
- administerTM needle length 600 pm
- CA nanobioSciences
- the oral thin film was applied, preferably with the simultaneous addition of 100 ⁇ l of Glandosane® to loosen the oral thin film.
- Oral thin films should always be dissolved as quasi-solids.
- the means for dissolving should preferably simulate the naturally produced saliva which causes the dissolving or at least dissolving of the oral thin film in vivo.
- Glandosane® was used for reasons of better solubility.
- Glandosane® artificial saliva is a spray for Use in the oral cavity for dry mouth and for oral care in the intensive care unit.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Medical Informatics (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102020122557.1A DE102020122557A1 (de) | 2020-08-28 | 2020-08-28 | Mucosa-Perforierung |
PCT/DE2021/100715 WO2022042799A1 (fr) | 2020-08-28 | 2021-08-25 | Perforation de la muqueuse |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4203916A1 true EP4203916A1 (fr) | 2023-07-05 |
Family
ID=77801423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21772669.4A Pending EP4203916A1 (fr) | 2020-08-28 | 2021-08-25 | Perforation de la muqueuse |
Country Status (11)
Country | Link |
---|---|
US (1) | US20240024647A1 (fr) |
EP (1) | EP4203916A1 (fr) |
JP (1) | JP2023546646A (fr) |
KR (1) | KR20230058452A (fr) |
CN (1) | CN116056738A (fr) |
AU (1) | AU2021334058A1 (fr) |
BR (1) | BR112023003399A2 (fr) |
CA (1) | CA3192247A1 (fr) |
DE (1) | DE102020122557A1 (fr) |
MX (1) | MX2023002424A (fr) |
WO (1) | WO2022042799A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115969771B (zh) * | 2023-01-31 | 2024-05-10 | 四川大学 | 一种可溶性载药微针及其制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10226494A1 (de) * | 2002-06-14 | 2004-01-08 | Lts Lohmann Therapie-Systeme Ag | Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen |
US7658728B2 (en) | 2006-01-10 | 2010-02-09 | Yuzhakov Vadim V | Microneedle array, patch, and applicator for transdermal drug delivery |
US20090099502A1 (en) * | 2006-04-07 | 2009-04-16 | Hisamitsu Pharmaceutical Co., Inc. | Microneedle Device And Transdermal Administration Device Provided With Microneedles |
US7785301B2 (en) | 2006-11-28 | 2010-08-31 | Vadim V Yuzhakov | Tissue conforming microneedle array and patch for transdermal drug delivery or biological fluid collection |
EP2271301A4 (fr) | 2008-03-27 | 2014-07-02 | Agigma Inc | Procédés et compositions pour la délivrance d agents |
US20110150946A1 (en) * | 2008-08-22 | 2011-06-23 | Al-Ghananeem Abeer M | Transdermal Delivery of Apomorphine Using Microneedles |
KR101033514B1 (ko) * | 2009-06-02 | 2011-05-09 | (주)마이티시스템 | 유연한 미세바늘 패치 시스템 및 그 제작방법 |
CN102039000B (zh) * | 2009-10-20 | 2015-08-26 | 苏州纳通生物纳米技术有限公司 | 一种透皮给药试剂盒 |
US20160128947A1 (en) | 2012-10-22 | 2016-05-12 | Stc. Unm | Bioadhesive films for local and/or systemic delivery |
WO2016155082A1 (fr) * | 2015-04-03 | 2016-10-06 | 苏州大学 | Système d'administration de médicament par micro-aiguille à fibroïne de soie et agent gonflant et son procédé de préparation |
US20190022022A1 (en) | 2016-05-05 | 2019-01-24 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
CN209316551U (zh) * | 2018-05-24 | 2019-08-30 | 优微(珠海)生物科技有限公司 | 一种可溶性微针贴片 |
CN108837299B (zh) * | 2018-07-18 | 2020-08-07 | 武汉大学 | 一种智能调节血糖的微针贴片及其制备方法 |
DE102019100483A1 (de) * | 2019-01-10 | 2020-07-16 | Lts Lohmann Therapie-Systeme Ag | Oraler Dünnfilm |
-
2020
- 2020-08-28 DE DE102020122557.1A patent/DE102020122557A1/de active Pending
-
2021
- 2021-08-25 BR BR112023003399A patent/BR112023003399A2/pt unknown
- 2021-08-25 US US18/023,771 patent/US20240024647A1/en active Pending
- 2021-08-25 KR KR1020237010423A patent/KR20230058452A/ko unknown
- 2021-08-25 CA CA3192247A patent/CA3192247A1/fr active Pending
- 2021-08-25 WO PCT/DE2021/100715 patent/WO2022042799A1/fr active Application Filing
- 2021-08-25 JP JP2023513605A patent/JP2023546646A/ja active Pending
- 2021-08-25 AU AU2021334058A patent/AU2021334058A1/en active Pending
- 2021-08-25 EP EP21772669.4A patent/EP4203916A1/fr active Pending
- 2021-08-25 CN CN202180053397.9A patent/CN116056738A/zh active Pending
- 2021-08-25 MX MX2023002424A patent/MX2023002424A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3192247A1 (fr) | 2022-03-03 |
MX2023002424A (es) | 2023-03-22 |
AU2021334058A1 (en) | 2023-05-11 |
DE102020122557A1 (de) | 2022-03-03 |
BR112023003399A2 (pt) | 2023-04-11 |
US20240024647A1 (en) | 2024-01-25 |
CN116056738A (zh) | 2023-05-02 |
KR20230058452A (ko) | 2023-05-03 |
JP2023546646A (ja) | 2023-11-07 |
WO2022042799A1 (fr) | 2022-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69622980T2 (de) | Bioadhäsives Arzneimittel zur kontrollierten Freisetzung von Wirkstoffen | |
DE2525061C2 (de) | Formkörper zur Abgabe eines Wirkstoffs und Verfahren zu dessen Herstellung | |
DE60129849T2 (de) | Bioadhäsiver schaumstoffilm mit hinhaltender wirkstoffreigabe | |
EP2029121B1 (fr) | Système thérapeutique percutané contenant des particules de principe actif avec un flux de principe actif accru | |
DE3237945A1 (de) | Pharmazeutische zusammensetzungen mit verzoegerter abgabe | |
EP1560564B1 (fr) | Systeme therapeutique multicouche d'administration par voie transmuqueuse | |
EP1191927A1 (fr) | Systeme a microreservoir, a base de polysiloxanes et de solvants hydrophiles et lipophiles | |
WO2022042799A1 (fr) | Perforation de la muqueuse | |
EP1638521A1 (fr) | Forme d'administration trans-muqueuse a irritation reduite des muqueuses | |
WO2019207067A1 (fr) | Film mince d'hygiène bucco-dentaire en forme de u | |
EP2632443B1 (fr) | Préparation de films orodispersibles | |
EP3582751B1 (fr) | Films orodispersibles structurés | |
DE10136781B4 (de) | Flache orale Darreichungsformen mit wirkstoffhaltigen Partikeln | |
WO2023094638A1 (fr) | Auxiliaire d'application d'un film orodispersible | |
WO2022152876A1 (fr) | Films orodispersibles | |
WO2022195044A1 (fr) | Film extra-fin enroulé à usage oral, à charge élevée en principe actif | |
WO2023094637A1 (fr) | Timbre oral à micro-aiguilles | |
DE102021100752A1 (de) | Oraler Dünnfilm | |
WO2022152877A1 (fr) | Film mince oral multicouches | |
WO2014090981A1 (fr) | Médicament topique utilisé pour le traitement des aphtes | |
WO2004041239A1 (fr) | Forme pharmaceutique d'administration par voie transmucosale |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230328 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40088542 Country of ref document: HK |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20231215 |